Jeff is CEO of a stealth Atlas NewCo. Previously he was a venture partner at Third Rock Ventures and held multiple executive roles at bluebird bio including chief financial and strategy officer over a 9-year period. Jeff has over 30 years of experience in leadership positions with established, emerging and start-up public and private life sciences companies. He previously served as chief business and financial Officer of Taligen Therapeutics, Inc. through its sale to Alexion Pharmaceuticals, Inc. Jeff currently serves on the Board of Directors at Tenaya Therapeutics and Tevard Biosciences and is an Executive Teaching Fellow at Boston University’s Questrom School of Business, teaching on topics of healthcare strategy and organizational development. He received his B.A. from Yale University and MBA from the Kellogg Graduate School of Management at Northwestern University.